A Randomized Phase III Clinical Trial For The Addition Of Docetaxel To Androgen Receptor Pathway Inhibitors In Patients With Metastatic Castration Sensitive Prostate Cancer And Suboptimal PSA Response (TRIPLE-SWITCH)
- Sponsor:
- Canadian Cancer Trials Group
- Sponsor Study ID:
- CCTG-PR26
- CTO #:
- 104186
- NCT Number:
- NCT06592924
- Phase:
- III
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Prostate
- Study Objectives:
- To compare overall survival in participants with mCSPC who are receiving standard of care ADT (between 6-12 months exposure) + ARPI and have suboptimal PSA response with those who recieve standard of care ADT + ARPI plus docetaxel chemotherapy.
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Becker, Kevin, at beckerke@musc.edu .
- Study Coordinator, Tucker, Renee, at tuckerr@musc.edu .
Trial opened at the following institutions:
Medical University of South Carolina